Answers are grounded in this paper and cite their sources.
OBJECTIVES: To evaluate the effect of methotrexate (MTX) co-administration with baricitinib (BAR) in rheumatoid arthritis (RA) treatment using a multicenter registry. METHODS: A total of 296 patients with RA treated with BAR were included (167 with MTX and 129 without MTX). Treatment effectiveness over 52 weeks was evaluated using propensity score-based overlap weighting to adjust for baseline differences. Group-based trajectory modeling (GBTM) was applied to identify distinct longitudinal response patterns. RESULTS: After overlap weighting, baseline characteristics were successfully balanced between groups (standardized mean differences <0.1). No significant differences were observed between the -MTX and +MTX groups in treatment retention (76.3% vs. 83.7%, p=0.213), CDAI scores at week 52 (5.7 [95% CI 4.2-7.1] vs. 5.8 [95% CI 4.5-7.1], p=0.90), or remission rates (32.1% vs. 34.5%, p=0.70). GBTM identified four distinct trajectories of disease activity; however, the distribution of MTX use did not differ across trajectory groups. CONCLUSIONS: After adjustment for baseline differences, MTX co-administration was not associated with improved clinical outcomes or response trajectories during BAR therapy. These findings may inform treatment decisions for patients unable to receive concomitant MTX.
No takes yet. Share an insight, caveat, or question.
Terabe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: